Cargando…

Comparative Study of Adverse Drug Reactions Associated with Filgrastim and Pegfilgrastim Using the EudraVigilance Database

SIMPLE SUMMARY: The most commonly reported adverse drug reactions (ADRs) related to filgrastim (FIL) and pegfilgrastim (PEG-F) were obtained and analyzed from the European EudraVigilance (EV) database. Frequently reported ADRs for FIL and PEG-F are pyrexia, bone pain, back pain, neutropenia and febr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rastogi, Shruti, Kalaiselvan, Vivekanandan, Bin Jardan, Yousef A., Zameer, Saima, Sarwat, Maryam
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8869538/ https://www.ncbi.nlm.nih.gov/pubmed/35205206 http://dx.doi.org/10.3390/biology11020340

Ejemplares similares

Hypersensitivity Reactions in Serious Adverse Events Reported for Paracetamol in the EudraVigilance Database, 2007–2018
por: Popiołek, Iwona, et al.
Publicado: (2019)

Analysis of Thrombotic Adverse Reactions of COVID-19 AstraZeneca Vaccine Reported to EudraVigilance Database
por: Tobaiqy, Mansour, et al.
Publicado: (2021)

Analysis of heat stroke and heat exhaustion cases in EudraVigilance pharmacovigilance database
por: Gamboa, Lorea, et al.
Publicado: (2023)

An algorithm to detect unexpected increases in frequency of reports of adverse events in EudraVigilance
por: Pinheiro, Luis C., et al.
Publicado: (2017)

Identifiability of Biologicals: An Analysis Using EudraVigilance, the European Union's Database of Reports of Suspected Adverse Drug Reactions
por: Correia Pinheiro, Luis, et al.
Publicado: (2021)

The Impact of Mandatory Reporting of Non-Serious Safety Reports to EudraVigilance on the Detection of Adverse Reactions
por: Candore, Gianmario, et al.
Publicado: (2021)

Post-Marketing Surveillance of Statins—A Descriptive Analysis of Psychiatric Adverse Reactions in EudraVigilance
por: Pop, Gabriela, et al.
Publicado: (2022)

Medication Errors: A Characterisation of Spontaneously Reported Cases in EudraVigilance
por: Newbould, Victoria, et al.
Publicado: (2017)

EudraVigilance Medicines Safety Database: Publicly Accessible Data for Research and Public Health Protection
por: Postigo, Rodrigo, et al.
Publicado: (2018)

Exploratory Study of Signals for Asthma Drugs in Children, Using the EudraVigilance Database of Spontaneous Reports
por: Baan, Esmé J., et al.
Publicado: (2019)

Comparative Safety Profiles of Oncology Biosimilars vs. Originators in Europe: An Analysis of the EudraVigilance Database
por: Nikitina, Victoria, et al.
Publicado: (2023)

Correction to: Medication Errors: A Characterisation of Spontaneously Reported Cases in EudraVigilance
por: Newbould, Victoria, et al.
Publicado: (2017)

Suspected oncologic adverse reactions associated with interleukin‐23 inhibitors in EudraVigilance: Comparative study and gender distribution
por: Calapai, Fabrizio, et al.
Publicado: (2023)

Comparison of adverse drug reactions among four COVID‐19 vaccines in Europe using the EudraVigilance database: Thrombosis at unusual sites
por: Abbattista, Maria, et al.
Publicado: (2021)

A Pharmacovigilance Study on the Safety of Axicabtagene Ciloleucel Based on Spontaneous Reports from the EudraVigilance Database
por: Rafaniello, Concetta, et al.
Publicado: (2023)

Pharmacovigilance of Risankizumab in the Treatment of Psoriasis and Arthritic Psoriasis: Real-World Data from EudraVigilance Database
por: Calapai, Fabrizio, et al.
Publicado: (2023)

Does additional monitoring status increase the reporting of adverse drug reactions? An interrupted time series analysis of EudraVigilance data
por: Segec, Andrej, et al.
Publicado: (2020)

Evaluation of quantitative signal detection in EudraVigilance for orphan drugs: possible risk of false negatives
por: Sardella, Marco, et al.
Publicado: (2019)

A Descriptive Analysis of Direct Oral Anticoagulant Drugs Dosing Errors Based on Spontaneous Reports from the EudraVigilance Database
por: Morgovan, Claudiu, et al.
Publicado: (2023)

Thrombotic Adverse Events Reported for Moderna, Pfizer and Oxford-AstraZeneca COVID-19 Vaccines: Comparison of Occurrence and Clinical Outcomes in the EudraVigilance Database
por: Tobaiqy, Mansour, et al.
Publicado: (2021)

Hypernatremia During Intravenous Treatment With Fosfomycin: A Retrospective Medical Record Review Study and an Analysis of Spontaneous Reports in the EudraVigilance Database
por: Scavone, Cristina, et al.
Publicado: (2022)

Disease-Modifying Therapies (DMTs) in Pregnant and Lactating Women with Multiple Sclerosis: Analysis of Real-World Data from EudraVigilance Database
por: Sportiello, Liberata, et al.
Publicado: (2023)

Characteristics and completeness of spontaneous reports by reporter's role in Germany: An analysis of the EudraVigilance database using the example of opioid‐associated abuse, dependence, or withdrawal
por: Jobski, Kathrin, et al.
Publicado: (2023)

Anaphylaxis rates following mRNA COVID-19 vaccination in children and adolescents: Analysis of data reported to EudraVigilance
por: Maltezou, Helena C., et al.
Publicado: (2023)

The Safety Profile of Filgrastim and Pegfilgrastim
por: Neumann, Theresa A., et al.
Publicado: (2011)

We Really Need Clear Guidelines and Recommendations for Safer and Proper Use of Aripiprazole and Risperidone in a Pediatric Population: Real-World Analysis of EudraVigilance Database
por: Rafaniello, Concetta, et al.
Publicado: (2020)

Safety profile of hydroxychloroquine used off‐label for the treatment of patients with COVID‐19: A descriptive study based on EudraVigilance data
por: Motola, Domenico, et al.
Publicado: (2022)

Reported congenital malformations after exposure to non‐tumour necrosis factor inhibitor biologics: A retrospective comparative study in EudraVigilance
por: Ghalandari, Nafise, et al.
Publicado: (2022)

Safety Monitoring of mRNA COVID-19 Vaccines in Children Aged 5 to 11 Years by Using EudraVigilance Pharmacovigilance Database: The CoVaxChild Study
por: Zinzi, Alessia, et al.
Publicado: (2023)

Preliminary evidence on the safety profile of BNT162b2 (Comirnaty): new insights from data analysis in EudraVigilance and adverse reaction reports from an Italian health facility
por: Gringeri, Michele, et al.
Publicado: (2021)

Efficacy and Safety of Filgrastim and Its Biosimilars to Prevent Febrile Neutropenia in Cancer Patients: A Prospective Study and Meta-Analysis
por: Rastogi, Shruti, et al.
Publicado: (2021)

A Pharmacovigilance Study Regarding the Risk of Antibiotic-Associated Clostridioides difficile Infection Based on Reports from the EudraVigilance Database: Analysis of Some of the Most Used Antibiotics in Intensive Care Units
por: Vintila, Bogdan Ioan, et al.
Publicado: (2023)

Pharmacovigilance Signals of the Opioid Epidemic over 10 Years: Data Mining Methods in the Analysis of Pharmacovigilance Datasets Collecting Adverse Drug Reactions (ADRs) Reported to EudraVigilance (EV) and the FDA Adverse Event Reporting System (FAERS)
por: Chiappini, Stefania, et al.
Publicado: (2022)

Evaluation of the Reported Rates of Severe Hypersensitivity Reactions Associated with Ferric Carboxymaltose and Iron (III) Isomaltoside 1000 in Europe Based on Data from EudraVigilance and VigiBase™ between 2014 and 2017
por: Ehlken, Birgit, et al.
Publicado: (2018)

Comment on ‘Evaluation of the Reported Rates of Severe Hypersensitivity Reactions Associated with Ferric Carboxymaltose and Iron(III) Isomaltoside 1000 in Europe Based on Data from EudraVigilance and VigiBase™ Between 2014 and 2017’
por: Schaffalitzky de Muckadell, Philip, et al.
Publicado: (2019)

Effectiveness of cytopenia prophylaxis for different filgrastim and pegfilgrastim schedules in a chemotherapy mouse model
por: Scholz, Markus, et al.
Publicado: (2009)

Filgrastim, lenograstim and pegfilgrastim in the mobilization of peripheral blood progenitor cells in patients with lymphoproliferative malignancies
por: Ria, Roberto, et al.
Publicado: (2014)

Chemotherapy-Induced Neutropenia in HIV Positive Patients with Lymphoma: Comparison of Pegfilgrastim with Daily Filgrastim Administration
por: Teofili, Luciana, et al.
Publicado: (2012)

Authors’ reply to Schaffalitzky de Muckadell and colleague’s Comment on “Evaluation of the Reported Rates of Severe Hypersensitivity Reactions Associated with Ferric Carboxymaltose and Iron (III) Isomaltoside 1000 in Europe Based on Data from EudraVigilance and VigiBase™ between 2014 and 2017”
por: Ehlken, Birgit, et al.
Publicado: (2019)

PB2416: EFFICACY AND SAFETY OF BIOSIMILAR PEGFILGRASTIM AFTER AUTOLOGOUS STEM CELL TRANSPLANT: A COMPARATIVE STUDY WITH BIOSIMILAR FILGRASTIM, LENOGRASTIM AND ORIGINATOR PEGFILGRASTIM
por: Marchesi, Francesco, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_sclvjq1dst7hsaslp5odiktba0